Q3 2015 · —
Revenue$340.87M$340.87M +11.2% vs Q3 2014+2.1% vs Q2 2015
Net Income$87.96M$87.96M +241.4% vs Q3 2014−0.2% vs Q2 2015
EPS Diluted$1.39$1.39 +239.0% vs Q3 2014−0.7% vs Q2 2015
Gross Profit$310,369,000+11.9%
Operating Income$131,532,000+126.6%
Operating Cash Flowderived$175,076,000+35.0%
Free Cash Flowderived$169,917,000+39.8%
Margins · derived
Gross margin91.1%+0.6 pt vs Q3 2014
Operating margin38.6%+19.7 pt vs Q3 2014
Net margin25.8%+17.4 pt vs Q3 2014
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2015 | Q3 2014 | Q3 2013 | Q3 2012 |
|---|---|---|---|---|
| Revenue | $340.87M | $306.58M | $232.16M | $175.52M |
| Net Income | $87.96M | $25.77M | $75.41M | $33.21M |
| EPS Diluted | $1.39 | $0.41 | $1.23 | $0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR